Compounds of formula (I)
and pharmaceutically-acceptable and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.
式(I)的化合物及其医药上可接受的、可
水解酯和酸加成盐,其中符号的定义为
MAP激酶
抑制剂,可用于治疗TNFα和IL-1介导的疾病,如类风湿关节炎和骨代谢疾病,如骨质疏松症。